Everolimus

Generic Name: Everolimus

Brand Names: Afinitor, Votubia, Zortress

Drug Type: Small Molecule

Chemical Formula: C_₅₃H_₈₃NO_₁₄

CAS Number: 159351-69-6

Unique Ingredient Identifier: 9HW64Q8G6G

Background: Everolimus is a derivative of Rapamycin (sirolimus), and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor. It is currently used as an immunosuppressant to prevent rejection of organ transplants. In a similar fashion to other mTOR inhibitors Everolimus' effect is solely on the mTORC1 protein and not on the mTORC2 protein.

Indication: Everolimus is indicated for the treatment of postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer (advanced HR+ BC) in combination with exemestane, after failure of treatment with letrozole or anastrozole.
...

Associated Conditions: Heart Transplant Rejection, Kidney Transplant Rejection, Liver Transplant Rejection, Progressive Neuroendocrine Tumors of pancreatic origin, Renal angiomyolipoma, tuberous sclerosis complex, Subependymal giant cell astrocytoma, tuberous sclerosis complex, Waldenstrom's Macroglobulinemia Refractory, Advanced Carcinoid tumor, Locally advanced Progressive Neuroendocrine Tumors of gastrointestinal origin, Locally advanced lung origin Progressive Neuroendocrine Tumors, Metastatic gastrointestinal origin Progressive Neuroendocrine Tumors, Metastatic lung origin Progressive Neuroendocrine Tumors, Refractory Advanced Renal Cell Carcinoma, Refractory, advanced Breast cancer, Unresectable gastrointestinal origin Progressive Neuroendocrine Tumors, Unresectable lung origin Progressive Neuroendocrine Tumors

Associated Therapies: -

Clinical Trials

Temozolomide + Everolimus in Newly Diagnosed, Recurrent, or Progressive Malignant Glioblastoma Multiforme

Phase 1

Completed

Conditions: Brain and Central Nervous System Tumors

First Posted Date: 2006-10-13

Last Posted Date: 2023-08-04

Lead Sponsor: NCIC Clinical Trials Group

Target Recruit Count: 32

Registration Number: NCT00387400

Locations: 🇨🇦
McGill University - Dept. Oncology, Montreal, Quebec, Canada
🇨🇦
Tom Baker Cancer Centre, Calgary, Alberta, Canada
🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada

and more 6 locations

Preservation of Renal Function in Liver Transplant Recipients With Certican Therapy

Phase 3

Completed

Conditions: Liver Transplantation

Interventions: Drug: everolimus
Drug: CNI
Drug: basiliximab

First Posted Date: 2006-09-19

Last Posted Date: 2015-02-06

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 276

Registration Number: NCT00378014

Locations: 🇨🇭
Novartis Investigative Site, Zurich, Switzerland

Nordic Everolimus (Certican) Trial in Heart and Lung Transplantation

Phase 4

Completed

Conditions: Disorder Related to Cardiac Transplantation

Interventions: Drug: Mycophenolic acid (MPA)/azathioprine (AZA)
Drug: Everolimus
Drug: Calcineurin inhibitors (CNI)
Drug: Steroids

First Posted Date: 2006-09-19

Last Posted Date: 2020-07-30

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 282

Registration Number: NCT00377962

Locations: 🇸🇪
Novartis Investigative Site, Lund, Sweden

Everolimus in Combination With Cyclosporine A and Prednisolone for the Treatment of Graft Versus Host Disease

Phase 1

Terminated

Conditions: Graft Versus Host Disease

First Posted Date: 2006-09-08

Last Posted Date: 2014-05-29

Lead Sponsor: University Hospital Tuebingen

Target Recruit Count: 10

Registration Number: NCT00373815

Locations: 🇩🇪
Medical Center, Hematology & Oncology, University of Tuebingen, Tuebingen, Germany

S0528 Lapatinib and Everolimus in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma

Phase 1

Completed

Conditions: Lymphoma
Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: everolimus
Drug: lapatinib ditosylate

First Posted Date: 2006-07-14

Last Posted Date: 2015-03-06

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 66

Registration Number: NCT00352443

Locations: 🇺🇸
University of California Davis Cancer Center, Sacramento, California, United States
🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
🇺🇸
University Cancer Center at University of Washington Medical Center, Seattle, Washington, United States

and more 3 locations

Comparison of CNI-based Regimen Versus CNI-free Regimen in Kidney Transplant Recipients.

Phase 4

Terminated

Conditions: Renal Transplantation

Interventions: Drug: Cyclosporin A (CsA)
Drug: Everolimus
Drug: Tacrolimus
Drug: Corticosteroids
Drug: Enteric Coated - Mycophenolate Sodium (EC-MPS)

First Posted Date: 2006-06-02

Last Posted Date: 2014-08-28

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 93

Registration Number: NCT00332839

Locations: 🇩🇪
Novartis Investigative Site, Muenster, Germany

Everolimus and Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Kidney Cancer

Phase 2

Completed

Conditions: Kidney Cancer

Interventions: Drug: Everolimus
Drug: imatinib mesylate

First Posted Date: 2006-05-31

Last Posted Date: 2017-10-26

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 23

Registration Number: NCT00331409

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

Efficacy and Safety of Everolimus in Recipients of Heart Transplants to Prevent Acute and Chronic Rejection

Phase 3

Completed

Conditions: Graft Rejection

Interventions: Drug: mycophenolate mofetil
Drug: everolimus
Drug: cyclosporine
Drug: corticosteroids

First Posted Date: 2006-03-08

Last Posted Date: 2012-08-16

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 721

Registration Number: NCT00300274

Locations: 🇺🇸
Hahnemann University Hospital, Philadelphia, Pennsylvania, United States
🇺🇸
Temple University Hospital, Philadelphia, Pennsylvania, United States
🇺🇸
Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States

and more 61 locations